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Development of resistance limits transferability of most anticancer therapies into curative treat-
ment and understanding mechanisms beyond it remains a big challenge. Many high resolution
experimental observations show enormous intratumor heterogeneity at molecular, genetic and cel-
lular levels which is made responsible for emerging resistance to therapy. Therefore, researchers
search techniques to influence development of intratumor heterogeneity, which requires understand-
ing its role within the context of integrative, logically consistent, framework, such as evolutionary
theory. Although it is agreed that intratumor heterogeneity increases probability of the emergence
of therapy resistant clones, more instructive role of its structure in the process of cancer dynamics
and metastasis is needed. In the paper, intratumor heterogeneity is viewed as a product of two,
in general stochastic, processes, evolutionary optimization and changing environment, respectively.
In evolutionary theory, common risk-diversifying strategy displayed by isogenic populations in un-
predictably changing environments is bet-hedging. We suggest, that the structure of intratumor
heterogeneity is evolutionary trait evolving to maximize the clonal fitness in changing (or uncer-
tain) environment and that its structure corresponds to bet-hedging strategy. We advocate our view
by reviewing and combining important cancer relevant concepts.
BACKGROUND
Despite broad acceptance of evolutionary theory as
a useful conceptual framework to understand fun-
damental features of cancer behavior [1–3], evolu-
tionary aspect of cancer is often overlooked in devel-
opment of novel therapeutic strategies [4]. Although
no disqualifying contradiction with evolutionary the-
ory has been found, the dis-appreciation of therapeu-
tic applicability of evolutionary theory might come
from exaggerated expectations from too straightfor-
ward (or intuitive) applications of basic evolutionary
concepts. More purpose exploitation of evolution-
ary nature of carcinogenesis in therapy necessitates
deeper analysis of universal evolutionary concepts
within the context of cancer data.
Many years since postulating the basic principles of
evolution by Darwin, a lot of questions in evolution
theory itself have remained open, such as selection
unit, genotype-phenotype mapping, interactions of
selection levels, the role of causation in evolution-
ary biology, etc [5–8]. As biological organisms were,
for a long time, the only ’experimental’ system to
study evolution, the principles of evolutionary the-
ory merged with the implementation details. Devel-
oping evolutionary theory from the basic principles
through the modern synthesis and genetic determin-
ism towards the central dogma of molecular biology,
the emphasis of the word ’gene’ has, step by step,
moved from its original meaning as ’the cause of an
inheritable phenotype characteristic’ to its present
meaning as the physical structure. This conceptual
change is a major source of present confusion in the
question of causation in evolutionary biology [5, 8]
and motivates researchers to concentrate on molec-
ular aspects of cancer evolution. On the other hand,
applications of evolutionary principles outside biol-
ogy, in the fields such diverse as optimization, soci-
ology, ecology, etc, the evolutionary principles must
be implemented in the case-dependent way. Neglect-
ing implementation details, evolutionary theory can
potentially predict universal evolutionary dynamics
across wide range of applications [9].
Many advanced tumors have poor clinical outcome
due to development of resistance to therapy. As ex-
perimental studies have revealed enormous intratu-
mor heterogeneity [10–12], it is intuitively agreed
that intratumor heterogeneity increases the proba-
bility of harboring a therapy-resistant phenotypes.
Consistently, while normal cells respond very sim-
ilarly to drugs, mechanisms of resistance of can-
cer cells are extremely diverse [13]. Deeper under-
standing of intratumor heterogeneity structure and
dynamics therefore poses real challenge to cancer
therapy. Cancer research concentrates mainly on
recognizing molecular mechanisms beyond intratu-
mor heterogeneity and their therapeutic exploita-
tion. More systemic (or functional) role which in-
tratumor heterogeneity plays in cancer initiation and
progression remains less often studied and relatively
poorly understood, limiting usually to its role in
Darwinian evolution of tumors.
Presented genetic data shows that tumors contain
complex combinations of low-frequency mutations
thought to drive the cancer phenotypes [14]. Pre-
vious studies showed that probably no prototypical
cancer genotype exists and every tumor carries a
unique set of mutations, indicating that multiple ge-
2netic pathways may lead to invasive cancer as would
be expected in a stochastic non-linear dynamical sys-
tem [15]. It has been demonstrated that selection
for in vitro drug resistance can result in a complex
phenotype with more than one mechanism of resis-
tance emerging concurrently or sequentially [16]. It
was reported that genotoxic stress induces several
cell death pathways, only part of which fall within
the classical definition of apoptosis [17]. Accordingly
to Witz and Levy-Nissenbaum [18], complexity of
the signaling cascades in tumor microenvironment
and the interactive cross-talk between these cascades
generate the feeling that ’anything that can happen
will’ and they suggest to apply tools employed in hy-
per complex systems analysis [18]. Lewis generalizes
that, in formally similar system of evolving bacteria,
all of the theoretically logical possibilities of antibi-
otic resistance seem to have been realized in nature
accomplishing the same task, which is to prevent the
antibiotic from binding to its target [19].
It was proposed that cancer cells may possibly need
only a modest number of phenotypic traits to deal
with all the constraints and evolve into a tumor [20].
Facing huge genomic heterogeneity and microenvi-
ronmental uncertainty, the question is if these com-
mon ”hallmarks of cancer” are present in all the cells
all the time [21]. Focusing on a few phenotypic traits
would crucially reduce dimensionality of the relevant
search space of all the possible dynamics. Never-
theless, as any cancer cell can have myriad genetic
causes, as natural selection selects for phenotype,
not genotype, and population changes depend on lo-
cal environmental selection forces [22], it leads, at
genetic level, to an undetermined problem. Deeper
insight into the problem requires correct interpreta-
tion of intratumor heterogeneity. If interpreted as a
noise hiding a common pattern, the effort to gener-
alize data from many samples of the relevant cancer
type to see the pattern is justified. If, however, het-
erogeneity represents redundancy, i. e. no common
pattern exists and each tumor has unique, neverthe-
less causative set of genes, to study cancer by re-
ducing heterogeneity may be a flawed approach [23].
If this is the case, the optimization problem solved
by cancer can be viewed as, in a sense, underdeter-
mined, which means that there are enough degrees of
freedom to find multiple reasonable fit solutions for
many environments, i. e. multiple physically realiz-
able solutions to the relevant mathematical problem.
In [24], Krakauer and Plotkin applied the quasis-
pecies model [25] and analyzed the evolutionary dy-
namics of redundancy and anti-redundancy in gen-
eral case. They proposed conditions which favor
evolution of redundancy or anti-redundancy, respec-
tively, and list mechanisms responsible for creating
redundancy and anti-redundancy at the cellular level
[24].
It is intuitively clear that owing to its heterogeneity,
evolving population of cancer cells can absorb and,
in conjunction with natural selection, evolve many
alternative solutions to many different environments,
representing an efficient computational system. Pro-
duced by combination of many sources, population
heterogeneity becomes extremely complex statisti-
cal quantity. The measures of heterogeneity may be
defined in many different ways most of them cho-
sen from the viewpoint of the statistical mechan-
ics of non-extensive systems based on entropy [26–
28]. Transforming heterogeneity into a tractable and
computable property of cellular populations provides
a rigorous starting point for determining which vari-
ation is random and which is meaningful [29].
The last decade has witnessed renewed interest of
cancer research community in hierarchical model of
cancer, well known as cancer stem cells (CSC) hy-
pothesis [30] claiming that cancer cells populations
are hierarchically structured with only a small sub-
population of the cells able to recapitulate tumor
from which they were derived. CSC seems to possess
self-renewal ability and reveal resistance against con-
ventional therapies [30–32]. As soon as the CSC hy-
pothesis was proposed, CSC have become viewed as
the target for therapeutic intervention [33, 34]. The
strategies rely on the possibility of precise enough
splitting of cancer cells population into CSC fraction
and non-CSC fraction. The original cancer stem cell
model suggested that CSC represent a subset of can-
cer cells population which is well distinguishable by
a limited number of cell-surface markers. During the
time, many controversial issues regarding their ori-
gin, proportions in cancer cells population, hetero-
geneity, flexibility of their state, etc. have emerged
[35–39] and the existence and role of CSC in cancer
initiation and progression remain a topic of intense
debate [40–45]. Accordingly to Badve and Naksha-
tri [46], CSC should be viewed as representing an
aggressive clone that has evolved during tumor pro-
gression, concluding that referring to these cells as
CSC is, actually, a matter of semantics. Similarly
Maenhaut et al. propose that the tumor propagating
cells are multiple evolutionary selected cancer cells
with the most competitive properties maintained by,
at least partially, reversible mechanisms, quantita-
tive rather than qualitative and resulting from a
stochastic rather than deterministic process [47]. If,
however, cancer cell stemness is defined by func-
tion [41, 44–46] instead of specific molecular struc-
ture, approaches relying on the possibility of precise
enough splitting of cancer cells population into CSC
fraction and non-CSC fraction may lack efficiency.
There is growing evidence that many solid tumors
may be composed of several distinct subtypes of tu-
mors, which may have distinct CSC [48, 49]. Genetic
heterogeneity of cancer stem cells [36, 50, 51] pro-
vides phenotypic and functional heterogeneity and
tempts to designate the cancer stem cells to be the
units of selection in the model of clonal evolution
[52]. From an evolutionary perspective, limitation of
3self-replicating capacity to a fraction of tumor cells
means that the effective population size is restricted
to this stem-like compartment, rather than encom-
passing a bulk of tumor cells [53].
REVERSIBLE STATE TRANSITIONS
A few papers proposed that some isogenic cancer
cells populations consist of phenotypically different
subpopulations and that cancer cells actually switch
between different phenotypes (or cell types) in re-
versible way [54–60], putting the concept of stemness
in question. In their influential paper, Gupta et al.
[61] report observation that the only population of
human breast cancer cells consists of three phenotyp-
ically different sub-populations (consisting of stem,
basal and luminal cells, respectively). Studying dy-
namics of these cell-types fractions, they found that
these stay, under stationary conditions, in equilib-
rium proportions. Moreover, if the cancer cells pop-
ulation is purified for any of the three cell types, the
equilibrium is rapidly re-established [61]. The pro-
gression towards equilibrium proportions would re-
quire implausibly high proliferation rates, therefore
they concluded that the progression towards equi-
librium was not due to differential growth rates of
cells in the respective states but rather to intercon-
versions between cell types [61]. Summarizing their
observations, Gupta et al. proposed a Markov model
of cell-state dynamics [61], which assumes that cells
within a population can exist in any one of M possi-
ble stable cell states (i. e. cell types) and under fixed
genetic and environmental conditions, cells transi-
tion from one state to another with interconversion
rates per unit time that are constant.
Identification of the cell-state dynamics with Markov
process [61] enables to study physical and evolution-
ary aspects of cancer dynamics separately. Cancer
research concentrates predominantly on the former,
physical, aspects, trying to understand details of
molecular mechanisms and genetic similarities be-
yond the cell types transitions. Assuming reported
observation, that genetically identical cells under
identical physical conditions differ in their response
to a given chemotherapeutic to an extent that may
impact on clinical response [62], probabilistic na-
ture of Markov model of the cell-state dynamics may
be, eventually, very appropriate. It follows common
mathematical behavior of Markov processes, such as
its convergence towards limiting distribution, which
is fully determined by underlying it transition ma-
trix. As each element of the transition matrix repre-
sents respective interconversion rate, i. e. the prob-
ability of a physical process, equilibrium cell types
proportions in cells population (hence non-genetic
heterogeneity) are fully determined by the transition
probabilities and do not depend on instantaneous
cell types proportions themselves. In this way, M
equilibrium cell types proportions are determined by
O(M2) interconversion rates which leads, however,
to underdetermined problem forM > 2. Despite the
fact that physical processes beyond the respective
transitions are certainly not independent each other,
huge number of degrees of freedom of the problem
still may leave opportunity to get any equilibrium
distribution of phenotypic proportions by multiple
sets of interconversion rates (i. e. alternative combi-
nations of the respective processes). Solving under-
determined inverse problems is for evolution, in gen-
eral, an easy task. Many forms and mechanisms of
phenotypic switching have been theoretically stud-
ied [63–68] and observed at molecular, genetic and
expression levels [69–73].
CANCER RELEVANT SELECTION UNIT,
TIMESCALE AND CAUSATION
Despite often referred observations that cancer cells
actually switch between different cell types in re-
versible way [54–60], heterogeneity is, in cancer bi-
ology, traditionally attributed to genetic variance,
implicitly implying one-to-one genotype-phenotype
mapping. Many authors propose that genetic het-
erogeneity is unlikely to be the major contributor to
phenotypic heterogeneity in general, but, underlying
heritable differences, it fuels tumor evolution [11].
As non-genetic mechanisms, such as gene expression
noise and multiplicity of stable states in gene net-
works, are responsible for phenotypic identities of
normal cells, it was suggested that non-genetic het-
erogeneity, can contribute to somatic evolution of
cancer cells, hence accelerating tumor progression
and development of therapeutic resistance [74–76].
Recently, the difference between two types of can-
cer cell instability, genetic and non-genetic, was ac-
cented and hierarchical link between the correspond-
ing spaces, the fitness and epigenetic landscapes, was
proposed [77]. Therein, each point in the fitness
landscape (i. e. genome) provides epigenetic land-
scape of unique topology. Due to its mathematical
complexity, each epigenetic landscape contains, sta-
ble areas (attractors) around stable cell-states [77],
viewed as cell types or phenotypes (disputed below).
Non-occupied attractors are not exposed to selec-
tion and, consequently, are not evolutionarily har-
monized with the needs of the tissue [77] and stay
pathological (or cancerous). If epigenetic landscape,
due to genetic mutations or tumor microenviron-
ment, changes, probability of the cell finding itself
in cancerous attractors may increase [77]. Consid-
ering the timescale in which mutations spread in a
cell population, non-genetic instability is made re-
sponsible for heterogeneity of cancer cell populations
[77]. This is consistent with the observation that the
population of isogenic cancer cells purified for one
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FIG. 1: Question of causality: is limiting distribution of the state-cell dynamics [61] just ’lucky’ coincidence rooted
incidentally in the complexity of epigenetic landscape or, on the contrary, is the transition matrix evolutionary
outcome of specific tumor microenvironment?
of the stable cell-states re-establish equilibrium pro-
portions of the cell types too fast to be explained by
differential growth alone [61]. Consequently, the role
of somatic evolution in cancer progression is put in
doubt [77].
Keeping in mind Theodosius Dobzhansky’s state-
ment ’Nothing in biology makes sense except in
the light of evolution’, we propose the eventual role
played by non-genetic heterogeneity in somatic evo-
lution of cancer. To understand intratumor hetero-
geneity from evolutionary viewpoint, fundamental
aspects of natural selection, namely selection unit,
timescale and causation must be reconsidered. If
somatic evolution is applied to explain cancer, can-
cerous features are implicitly attributed to a cell
which is taken as cancer-relevant selection unit and
its fitness is identified with its reproduction capabil-
ity. Assuming one-to-one genotype-phenotype map-
ping, current cancer research focuses on differences
in metabolic pathways responsible for cancer pheno-
type of the cell in order to distinguish cancer and
normal cells as well as to predict proximate behav-
ior of cancer cells. However, the focus on differences
between the normal and cancer cells may be not ad-
equate enough, as it was observed that (at least)
some isogenic cancer cells populations consist of phe-
notypically different subpopulations [61], which im-
plies cell’s multistability (or one-to-many genotype-
phenotype mapping).
The term ’phenotype’ is often used in very intuitive
way, denoting usually observable traits of the cell,
which are assumed to be static. If alternative sets
of observable traits expressed by the same genome
is observed, each of them is viewed as an alternative
phenotype, and the change of phenotype without ge-
netic cause is interpreted as ’phenotypic switch’. De-
spite being appropriate in many biological contexts,
if evolutionary theory is to be applied in cancer bi-
ology, the term ’phenotype’ must be reconsidered.
Evolution is based on the general premise that any
population of entities which reveal variation, repro-
duction, and heritability may evolve [78]. The origi-
nal biological meaning of a gene referred to the cause
of an inheritable phenotypic characteristic [5]. It
implies, that the genome, as a set of genes, refers
to the cause of inheritable phenotype as a whole.
The above evolutionary premise is formally fulfilled
not only when the unique cell-type expressed by the
genome is taken as phenotype, but, as well, if the
epigenetic landscape, corresponding to the genome
as its unique cause, is assumed to be the phenotype.
In the latter context, the term ’phenotype’ encom-
passes all the relevant features of the epigenetic land-
scapes, such as the repertoire of attractors (i. e. cell
types), the heights of barriers between them, etc.
The fitness of the genome relates to the phenotype-
relevant timescale. At proximate timescale, its phe-
notype (i. e. a cell-type) is the outcome of spe-
cific molecular mechanisms and its fitness is obvi-
ous. At longer timescale, after the genome pro-
duced a lineage of reasonable size, the size of its
clone corresponds to the fitness of the genome (at
this timescale). Obviously, evolutionary success (or
failure) of the cell at short timescale does not nec-
essarily correlate with its evolutionary success on
long timescale. To quantify possible outcome of
lineage (or clone) evolution in a more quantitative
way, Palmer and Feldman introduced two metrics,
k-fitness and k-survivability [79]. The former quan-
tifies probability of increase of the size of the re-
spective lineage after k generations, the latter re-
lates to the likelihood that the species will avoid ex-
tinction after k generations. If k increases, k-fitness
of the cell depends more and more on the even-
tual interaction of the cells in the clone. Regarding
the timescale at which cancer has effects (cancer-
relevant timescale), the clone seems to be more rel-
evant structure to determine the genome fitness.
Leaving precise quantification of cancer-relevant
timescale to further research, we ask how general
evolutionary top-down causation [8] applies in can-
cer? At proximate timescale, the genomes’ fitnesses
depend on their respective ’built-in’ molecular ma-
chinery. On the other hand, molecular machinery
has been selected accordingly to the evolutionary ad-
vantage they conferred to the ancestors of the respec-
tive genomes (Fig. 1) in the past. The above recon-
sideration of cancer-relevant selection unit, timescale
and causation imply what is the selection force evolv-
ing epigenetic landscape and what is the optimum
repertoire of stable cell-states (i. e. cell types)
conferring to the cell the highest fitness at cancer-
relevant timescale.
BET-HEDGING
Markov model of the cell-state dynamics by Gupta
et al. [61] implies that non-genetic heterogeneity in
isogenic cancer cells population (i. e. cancer clone)
is actually determined by the probabilities of tran-
5sitions between different cell types, i. e. by the
transition matrix of Markov process, and are not
bound to genetic polymorphism. The cell types cor-
respond to stable cell-states (or attractors) in the
epigenetic landscape as conceptualized by Huang
[77]. In this way, genetically coded transition matrix
prescribes the sizes of the cell types fractions (hence
non-genetic heterogeneity) in any possible tumor mi-
croenvironment, and, from the evolutionary view-
point, the fitness of the genome at the cancer rele-
vant scale. As the cell types, in general, differ in their
growth (and other) properties, the distribution of
the cell states in the clone (non-genetic heterogene-
ity) becomes evolutionary important. To sum up,
the cells evolve transition matrix producing the pro-
portions of the cell types so that the clone increases
at maximum rate. During their evolution the cells
inevitably interact, which is traditionally viewed as
’cooperation’ in the case of normal cells, while the
cancer cells are often said to behave ’selfishly’, [80]
revealing specific prototypical features [20]. It was,
however, proposed as well, that genetically distinct
tumor cells cooperate as well to overcome certain
host defenses by exchanging different diffusible prod-
ucts [81]. Cooperation does not imply equality of the
cells in the clone but rather a specialization of the
cells to diverse roles, which increases clonal fitness.
In the conceptual model of group selection [6], pure
cooperator groups grow faster than pure defectors
groups, whereas in any mixed group, defectors repro-
duce faster than cooperators, i. e. selection on the
lower level (within groups) favors defectors, whereas
selection on the higher level (between groups) favors
groups consisting of cooperators [6].
Inspired by the above model of cooperation [6], we
suggest that the cancer cell, its clone being the evo-
lutionary winner at the relevant timescale, produces
the clone of well ’cooperating’ cells, and propose
what kind of cooperation between cancer cells can be
expected. Instead of interpreting specific biochem-
ical reactions as cooperative or selfish, cooperation
is viewed in a more general way - as a coordinated
action. This view enables its statistical interpre-
tation as mutually correlated dispersal of the cell
states in the state space. The observation by Gupta
[61] implies, that the cell types equilibrium (i. e.
non-genetic heterogeneity) in isogenic clone of cells
can be established by switching between a few pos-
sible states in a reversible way. Assuming that the
cells in different states differ in their proliferation
efficiency, intraclonal cooperation is determined by
the cell-states heterogeneity when the cells in differ-
ent states contribute to the clone growth by, in gen-
eral, different amounts. Different environments con-
fer different growth to the clones with different het-
erogeneity structure - in some environments clones
consisting of the cells in the same state may provide
faster clonal growth, while in the others more spe-
cialization (bound to specific structure of cell-states
heterogeneity) leads to faster growth of the clone.
In this view, non-genetic heterogeneity becomes evo-
lutionary trait and the fundamental question arises
what heterogeneity structure gives to the cell the
highest fitness (measured as the size of its clone).
From the viewpoint of evolutionary biology, phe-
notypic heterogeneity is an adaptation to environ-
mental uncertainty and phenotypic diversification
enables species to survive environmental adversity
[82]. Each phenotype (or, in here applied concep-
tualization, cell-type) proportion can be viewed as
an investment of certain portion of population’s re-
productive effort [83]. Two fundamental evolution-
ary strategies of population adapting to environ-
mental uncertainty are well known [83]. The for-
mer, generalist, produces constant phenotype which
has been reasonably fit in any relevant environment.
The latter, the bet-hedging strategy, generates non-
genetic phenotypic diversity in the population pro-
ducing phenotypes accordingly to probability dis-
tribution matching the distribution of the environ-
ments rewarding (in a sense of fitness) the respec-
tive phenotypes in the past. One can find instruc-
tive analogy with risk diversifying strategy in port-
folio management. Facing uncertain future, investor
divides his budget into a few (or many) assets in-
stead of the only, whatever probable, asset to pro-
tect himself against fatal loss. Optimum investment
strategy must somehow balance predictability of as-
sets’ prices with the cost of portfolio’s restructuring.
Optimal portfolio depends on the dynamics of the
trends, and, at the same time, the investor’s capa-
bility to restructure his ’portfolio’. It is of the utmost
importance that the bet-hedging strategy is realized
as alternative expressions of the only selection unit,
not as a form of genetic polymorphism [84].
In laboratory studies of yeast and bacteria, the rate
of phenotypic switching has appeared to adjust to
match the frequency of environmental changes [72].
In their model of survival in changing environments
[64], Kussell et al. demonstrated that the optimal
switching between normal cells and bacterial per-
sister cells, characterized by slow growth and in-
creased ability to survive antibiotic treatment, de-
pends strongly on the frequency of environmental
change and only weakly on the selective pressures of
any given experiment [64]. It is consistent with the
finding that a critical feature of the process of tumor
progression is selection of cells that can escape from
resource limitations by achieving a relative microen-
vironmental independence [85].
To sum up, the bet-hedging strategy [86] is a univer-
sal risk-diversification strategy evolved in the popu-
lations which face uncertain future and/or environ-
ment [87–89]. Assuming formal similarity of evolv-
ing cancer cells population with the above evolution-
ary systems, we identify non-genetic heterogeneity
corresponding to the observed equilibrium distribu-
tion of the cell types in isogenic cancer cells popula-
6tion [61] with the bet-hedging strategy. This identi-
fication is motivated by the observation that a rapid
progression towards equilibrium proportions would
require implausibly high proliferation rates and can-
not be explained by differential growth rates of the
clones of cells in the respective states, but rather to
interconversion between states [61]. Moreover, non-
genetic heterogeneity develops at the timescale in
which mutations barely spread in a cell populations
[77].
To propose the role of non-genetic heterogeneity
in clonal evolution of cancer, selection force which
pushes the cell types proportions into the ”optimum
investment profile” in the respective environment,
corresponding to the respective environmental fre-
quencies, must be identified. Applying the above
conceptualization by Huang [77], each the genome
represents epigenetic landscape of unique topology,
with the repertoire of attractors (i. e. cell types)
as a fundamental mathematical feature. These at-
tractors are separated by the barriers which heights
determine probabilities of transition between them.
In the conceptualization by Markov model [61], the
repertoire of attractors corresponds to the limiting
distribution of Markov model and the heights of the
barriers to its transition probabilities.
On the other hand, environment predetermines op-
timum investment profile, which, if occupied by the
respective (optimum) proportions of cancer cells,
maximizes growth of the clone. In bet-hedging the-
ory, the strength of selection towards the optimal
bet-hedging strategy depends on how far the resi-
dents are from the optimal investment profile [83].
Straightforwardly, the fitness of the cancer cell is
given by the deviations of the cell types proportions
in its clone from the optimum bet-hedging propor-
tions at cancer-relevant timescale. As the cell types
proportions (hence the clone’s cell-state heterogene-
ity) are determined by the rates of interconversions
between states [61], i. e. by the probabilities of spe-
cific physical processes, the genetically coded molec-
ular mechanisms are under selection pressure prefer-
ring those which provide heights of the barriers be-
tween attractors leading to the optimum cell types
fractions as required by the environment dynamics.
EVOLUTIONARY OPTIMIZATION
In 1932, Sewall Wright conceptualized evolution as
a search process through the astronomically huge
search space of all the possible combinations of genes
[91]. Assigning a fitness value (a quality measure) to
each genetic combination, the evolution was identi-
fied with a search for the highest peak (maximum
fitness) in so-called fitness landscape. In this way,
Wright linked evolution with the field of optimiza-
tion as conceived in engineering and economy [9],
initiating the new branch of stochastic optimization
techniques, presently known as evolutionary algo-
rithms (EA) [92]. Despite the fact that in evolution-
ary optimization one purposely applies evolutionary
principles to evolve population of candidate solu-
tions, while biological evolution is straightforward
consequence of mere existence of the population of
biological replicators (genomes), both the processes
depend on universal aspects of fitness landscape. EA
analyze the above features in implicitly abstract way,
while in biological evolution they are bound to spe-
cific molecular machinery which complicates their
analysis. Being applied in many different contexts,
EA have significantly enriched evolutionary theory
by sharpening the above ”substrate-free” aspects of
evolutionary dynamics.
In real-world optimization problems (including bi-
ological evolution) each fitness evaluation requires
nonzero resources and must be attained within af-
fordable time interval, which limits number of fitness
evaluations. On the other hand, keeping in mind
the fitness landscape uncertainty, rational strategy
is exploring, with some probability, also not yet eval-
uated parts of the search space. Uncertainty of sta-
tionary fitness landscapes decreases proportionally
to the number of fitness evaluations, therefore the
typical strategy is to allocate, during the optimiza-
tion, increasing number of trials to the observed best
solution, and let explorative power of the algorithm
vanish. But the question emerges how fast should
the ratio between exploration and exploitation as-
pects decrease during optimization? The problem is
known as the exploration vs. exploitation dilemma
(or the optimal trial allocation) and optimization
techniques differ in their way of solving it (Fig. 2).
Blind search (Fig. 2A) resigns exploitation prevent-
ing it from sticking in local optima but, at the same
time, results in very low efficiency. Gradient search
(Fig. 2B) always continues uphill, maximizing ex-
ploitation but it fails with high probability if the
fitness landscape contains more local optima. Simu-
lated annealing [90] (Fig. 2C) represents some com-
promise, starting as random search, decreasing con-
tinuously probability of acceptance of less fit points,
converging, eventually, in global optimum. Obvi-
ously, efficiency of sampling strategies crucially de-
pends on dimensionality, ruggedness, modality, sta-
tionarity, etc of the respective fitness landscape.
The problem of the optimal allocation of trials is es-
pecially challenging if the fitness landscape is chang-
ing, which is the crucial feature of biological fitness
landscapes. Facing uncertain future, optimization
procedure must maintain nonzero explorative ability.
To be efficient in changing fitness landscape, an opti-
mization procedure must i) detect change in the fit-
ness landscape (exploration), and, ii) appropriately
respond to it (exploitation). Due to nonzero detec-
tion and response time, tracing the optimum in dy-
namic optimization problem always expects nonzero
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FIG. 2: Examples of different sampling strategies. (A) blind search which maximizes exploration but completely omit
exploitation, (B) gradient search maximizing exploitation with exploration represented just by the determination of
gradient, (C) simulated annealing [90] trying to balance exploration with exploitation. In (D), constant ’sentinels’
are added to prevent shrinking of the search space [93]. In A,B and C, the sampling points are generated in serial
way, in D they represent population and are evaluated in parallel.
time correlation of fitness landscape which can be
exploited. The maximum entropy principle states,
that, if the probability distribution of random vari-
able is not known, the probability distribution which
best represents the current state of knowledge is the
one with the largest information theoretical entropy.
It implies preemptive distribution of the trials in evo-
lutionary algorithms designed for dynamic environ-
ments. They keep fraction of candidate solutions,
denoted as sentinels, unchanged [93]. The sentinels
are population members that are statistically rea-
sonably (in the above sense) distributed through the
search space upon initialization, and kept in popu-
lation to produce new population members through
selection, but themselves are neither mutated nor re-
placed [93]. The sentinels themselves are, in average,
neither more nor less fit than other solutions in the
population. Their added value consists in prevent-
ing, in conjunction with the other sentinels, shrink-
ing of the search space (Fig. 2D), i. e. maintaining
the exploratory power of the algorithm.
SUMMARY
Clonal evolution model for tumor progression by
Nowell [1] says that within a population of tumor
cells natural selection, which favors cells that have
acquired the most aggressive phenotype, occurs. To
make this predication more applicable, better under-
standing what ’the most aggressive’ means is neces-
sary. As soon as the CSC hypothesis was proposed
[30], the subpopulation of CSC was alleged to be the
most competitive tumor fraction, and, consequently,
tumor evolution was attributed to it. Despite its
universality is still debated, the CSC hypothesis im-
plies basic hierarchical structure of intratumor het-
erogeneity. Evolving cancer cells population reveals
the structure of heterogeneity (CSC vs. non-CSC
fractions) similar to the structure of population het-
erogeneity purposely applied in evolutionary opti-
mization to make optimization procedure more ef-
ficient in changing fitness landscapes [93, 94]. This
is not surprising, as the link between evolution and
optimization was made long time ago [91]. To sum
up, the intratumor heterogeneity structure of cancer
clone (being the evolutionary winner) has balanced
optimally exploration of the search space with its
exploitation during cancer-relevant time period.
Cancer heterogeneity has been for a long time
viewed as the consequence of genetic heterogeneity.
Presently, an opinion is emerging that the stemness
of cancer cells corresponds more to function state in-
stead of distinguishable genetic (or epigenetic) pat-
tern. This view is supported by reversible stochastic
switching between cell states in cancer cells popu-
lation [54–58, 61]. The results by Gupta et al [61]
show, that the specific cancer genome encodes, at the
same time, three alternative stable cell types, one of
them being the ’stem’ state, and switching between
them creates, in stationary environment, equilibrium
proportions of the cell types. In this way non-genetic
heterogeneity is responsible for cancer and some pa-
pers present doubts about the role of somatic evolu-
tion in cancer.
In the paper, the equilibrium cell types proportions
are viewed to be more refined structure of intratu-
mor heterogeneity, beyond the basic division into
8CSC and non CSC fractions. The genome stays the
main protagonist (i. e. selection unit) in the evolu-
tion of cancer cells, with non-genetic heterogeneity
of its eventual clone being the crucial adaptive trait
at cancer-relevant timescale. From the viewpoint of
evolutionary biology, phenotypic heterogeneity is an
adaptation to environmental uncertainty and phe-
notypic diversification enables species to survive en-
vironmental adversity. One of the observed and
well studied strategies of population diversification
in changing environment is the bet-hedging strategy
[83, 84, 86], which divides reproductive investment in
each environment to fit the respective environmental
frequencies in the past. Straightforwardly, we sug-
gest the hypothesis that non-genetic heterogeneity in
cancer cells population evolves towards the univer-
sal bet-hedging diversification strategy. Affirmative
answer to the hypothesis necessitates determination
of the optimum bet-hedging profile in specific can-
cer case during some relevant past, which is the task
far from trivial. Bound to the same evolving struc-
ture, the genome, the two components of phenotypic
heterogeneity (genetic and non-genetic) interact in
complex way, which dramatically complicates their
more rigorous analysis.
How can be the affirmative answer to the question in
the title helpful? Having attributed cancer dynamics
to an appropriate universal dynamics (such as here
proposed bet-hedging), one can, eventually, apply its
general features to influence the process by modify-
ing fitness landscapes in mathematically more pur-
poseful way. It is known that diversification strategy
adopted by evolving populations depends on the en-
vironment [83]. Under some environments dynam-
ics the generalist strategy are more successful than
bet-hedging [83]. Straightforwardly, purposeful ma-
nipulation with statistical features of environment
(hence fitness landscape) dynamics, may provide di-
versification strategy which is less fatal and/or bet-
ter controllable.
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